-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Good News! Shijiazhuang Sihua Pharmaceutical’s Metronidazole and Sodium Chloride Injection Has Passed Evaluation, with Packaging Design Leading the Industry.
Category:
发布时间：2022-09-28
【概要描述】
On September 28, Shijiazhuang Sihua Pharmaceutical Co., Ltd. received another national drug registration approval for its upright polypropylene infusion bag–packaged metronidazole sodium chloride injection (250 mL: 1.25 g and 100 mL: 0.5 g), securing yet another “entry pass” for participation in the national centralized drug procurement program.
Autumn is the season of bountiful harvests, and Shijiazhuang No. 4 Pharmaceutical Co., Ltd. has been receiving one encouraging update after another on its R&D and innovation achievements. In September, following the approval of two specifications of metronidazole sodium chloride injection in polypropylene infusion bottles—250 mL: 1.25 g and 100 mL: 0.5 g—as well as approval for mecobalamin injection (1 mL: 0.5 mg) and valsartan–amlodipine tablets (Formulation I), all of which were deemed to have passed the evaluation of generic drug quality and therapeutic equivalence, the company once again secured national drug registration approval on September 28 for metronidazole sodium chloride injection in upright polypropylene infusion bags—also available in 250 mL: 1.25 g and 100 mL: 0.5 g—thereby obtaining another “entry ticket” to participate in the national centralized drug procurement program.
According to available information, metronidazole sodium chloride injection is primarily used in clinical practice for the treatment of anaerobic bacterial infections. Previously, Shijiazhuang Sihua Pharmaceutical’s metronidazole sodium chloride injection—available in two packaging formats, multilayer co-extruded film infusion bags (250 ml: 1.25 g and 100 ml: 0.5 g) and polypropylene infusion bottles—successfully passed the National Evaluation of Quality and Therapeutic Equivalence for Generic Drugs in February 2021 and September 2022, respectively. With the recent approval of the upright polypropylene infusion bag–packaged formulation (250 ml: 1.25 g and 100 ml: 0.5 g), Shijiazhuang Sihua Pharmaceutical has now achieved a leading position among domestic pharmaceutical companies in terms of the number of approved packaging formats for this product.
Over the past two years, Shijiazhuang Sihua Pharmaceutical has leveraged a series of business-friendly policies introduced by the Shijiazhuang municipal government to spearhead breakthroughs in the biopharmaceutical industry. The company has steadily increased its R&D investment, coordinated efforts across multiple fronts—including generic drugs, innovative medicines, active pharmaceutical ingredients, biologics, and pharmaceutical packaging materials—and successfully tackled a number of critical “bottleneck” technologies. As a result, a steady stream of innovative achievements has emerged, bringing the company’s R&D portfolio into a concentrated phase of commercialization and value realization. Since the beginning of this year, the company has obtained 32 product approvals, including 22 for finished dosage forms, and a total of 29 drug products spanning 38 specifications have either passed or been deemed to have passed the National Evaluation of Quality and Therapeutic Equivalence for Generic Drugs. With R&D efficiency and approval rates that lead the industry, these innovations continue to strengthen the company’s core capabilities, empower it to move up the value chain, and position it for sustained growth at the mid- to high-end segments.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091